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Eosinophils are key contributors to Th2-associated pathologies
such as allergic asthma and rhinitis. They also function as effectors
in the innate immune response through the expression of Toll-like
receptor.1 Recently, several studies have indicated that eosinophils
act as both effectors and regulators of the Th1/Th2 balance through
interferon (IFN)-g and interleukin (IL)-10 production2 or as
antigen-presenting cells.3 However, their exact contribution to
Th2-associated pathologies such as asthma and Th1-associated pa-
thologies remains unclear. Indeed, Kobayashi et al.4 reported that
the development of airway hyper-responsiveness (AHR) associated
with the allergic response is prevented in hypereosinophilic IL-5
transgenic (Tg) mice.
To delineate the functional role of inactivated or activated eosin-
ophils in airway inﬂammation, we employed adoptive eosinophil
transfer5 using inactivated and activated eosinophils puriﬁed
from the spleens of IL-5 Tg mice immunized with ovalbumin
(OVA) or vehicle (phosphate-buffered saline; PBS) by an intraperi-
toneal injection (Fig. 1A). Puriﬁed eosinophils were transferred into
naïve recipient mice by one or four intratracheal administrations
(Fig. 1B). Recipient animals were analyzed 72 h after the ﬁnal
administration.
We previously reported5 that airway inﬂammation and AHR
are induced upon the transfer of activated, but not inactivated,
eosinophils into naïve wild-type (WT) recipient animals. Simi-
larly, adoptively transferred activated eosinophils promoted
lung inﬂammation, ﬁbrosis, collagen deposition, and AHR in se-
vere combined immunodeﬁciency (SCID) recipients, excluding
the inﬂuence of lymphocytes.5 These data indicate that inactive
eosinophils play only a minor role. In this report, to gain insight
into the role of the immune response in eosinophil-induced
airway inﬂammation, we proﬁled cytokine and transcription fac-
tor expression in the lung following eosinophils transfer. Inter-
estingly, IFN-g expression was signiﬁcantly increased in the
lungs of both SCID and WT recipients.5 As shown in Fig. 2A,
IFN-g was the only cytokine that was differentially expressed in
lungs from WT mice that received inactivated or activated eosin-
ophils. These data suggest that eosinophil-derived IFN-g is a key
mediator in this model. Therefore, we focused on the functional
role of IFN-g in this model of lung inﬂammation and developed
an IFN-g-deﬁcient IL-5 Tg mouse to further investigate the func-
tional role of endogenous IFN-g in eosinophils.Peer review under responsibility of Japanese Society of Allergology.
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vated eosinophils treated with an anti-IFN-g receptor antibody
that blocked IFN-g signaling immediately prior to transfer into
IFN-g-deﬁcient recipients resulted in a total abrogation of
eosinophil-induced lung inﬂammation, whereas IFN-g neutraliza-
tion in recipients led to partial inhibition.5 Moreover, we showed
that, low concentrations of IFN-g prolonged eosinophil survival
invitro,whereashigh concentrations inducedeosinophil apoptosis.5
These data suggest that IFN-g has a dual effect as both an activator
and an inhibitor of eosinophils depending on its concentration.
Together, these ﬁndings imply that activated eosinophil-derived
IFN-g is a keymediator in the development of airway inﬂammation,
despite the fact that eosinophils usually accumulate in the context of
Th2 pathology. Actually, we showed that activated eosinophils, pu-
riﬁed fromspleen of OVA sensitized IL-5 Tgmouse, signiﬁcantly pro-
duced IFN-g, compared with inactivated eosinophil.5
Regarding the Th1/Th2 balance, in Th1 dominance, IFN-g is
considered to inhibit the development of Th2 pathologies with
eosinophilia.6 However, an experimental study on using animal
model of asthma7 demonstrated that IFN-g contributes to the
development of allergic lung inﬂammation particularly in the
chronic phase. These discrepancies may be due in part to the bio-
logic characteristics of IFN-g, such as its dual effect. Indeed, as sup-
ported by our in-vitro results, Ishihara et al.8 showed that
recombinant human IFN-g upregulated CD69 and eosinophil
cationic protein expression. These data suggest that IFN-g not
only modulates Th1/Th2 pathology but also contributes to the
persistence and chronicity of airway inﬂammation in a global
Th2-pathologic context.
Recently, an interesting and extensive genome-wide association
study of asthmatic patients inWestern countries reported that lung
dysfunction, reﬂected by forced expiratory volume in 1 s, correlates
with the activity of Th1 rather than Th2 pathway genes, such as IL-
13, TSLP, IL-33, and IL-1 receptor-like 1.9 Thus, the authors proposed
a “two-step asthma progression genetic model”. The ﬁrst step is the
induction of a Th2-dominant response. Then, in the second step,
genetic variation in the Th1 pathway and/or airway remodeling in-
ﬂuence asthma severity.9 This report indicates that the Th1 and Th2
activation proﬁles are mixed, particularly in the chronic phase,
although the trigger is Th2 dominance. Furthermore, Steinke
et al.10 reported that IFN-g was prominently expressed in aspirin-
exacerbated respiratory disease, and that most IFN-g, derived
from eosinophils themselves, is synergized with IL-3, IL-5 and
CysLTs expression. Consistent with these reports, as shown in
Fig. 2B, we found that the expression of both Th1-associated
(IFN-g) and Th2-associated (IL-13) cytokines was signiﬁcantlyevier B.V. All rights reserved.
Fig. 1. Experimental design for eosinophil transfer. (A) Inactivated and activated eosinophils (Eos) were puriﬁed from the spleens of interleukin-5 transgenic mice following three
intraperitoneal injections of ovalbumin or phosphate-buffered saline (PBS). Puriﬁcation of eosinophil was >90%, and contaminating cells are mainly neutrophils but not lympho-
cytes and monocytes. (B) The upper and lower panels show the short- and long-term protocols, respectively. In the short-term protocol, PBS or 2  107 inactivated or activated Eos
were transferred into naïve recipient mice in a single intratracheal (i.t.) administration. In the long-term protocol, PBS or activated Eos was transferred into naïve recipients in four
i.t. administrations in every week. Recipient mice were sacriﬁced 3 days later after the completion of i.t. administrations in both protocols.
Fig. 2. Cytokine proﬁling in the short- and long-term protocols. (A) and (B) show the short- and long-term protocols. (A) mRNA expression of cytokines and transcription factors in
the lungs from naïve Balb/c were analyzed 72 h after phosphate-buffered saline (PBS; open bar, n ¼ 4) or 2  107 inactivated (gray bar, n ¼ 7) or activated (black bar; n ¼ 5) Eos
administration. This data is a partial revision of Figure 3 of Reference 5. (B) Similar analysis performed with PBS (open bar, n ¼ 3) or 2  107 activated Eos (black bar, n ¼ 3). Data in
both models are shown as the mean fold induction over PBS-treated recipient mice (n¼ 3e4). Statistical signiﬁcance was determined by using the ManneWhitney test. The symbols
* and y indicate a statistically signiﬁcant difference from PBS-treated recipient mice and a statistically signiﬁcant difference between recipients of inactivated and activated Eos,
respectively (p < 0.05).
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factors such as T-bet and GATA-3 were not altered. To investigate
the discrepancy among the expression levels of cytokines and tran-
scriptional factors in this model, additional experiments will be
required. Interestingly, Vale-Pereira et al.11 reported that the
expression level of both GATA-3 and T-bet in the long-lasting
asthma in the elderly was lower than that of healthy group. Their
report might support to this discrepancy.Together, our results imply that eosinophil-derived IFN-g is an
important mediator of lung inﬂammation that also modulates
Th1/Th2 balance. We propose that delineation of the functional
role of eosinophils through Th1-associated cytokines such as
IFN-g will not only clarify the mechanisms underlying eosino-
philic inﬂammation but also assist in the development of new
therapeutic strategies, in particular for chronic eosinophilic
inﬂammation.
Letter to the Editor / Allergology International 64 (2015) S71eS73 S73Acknowledgments
We are grateful to the members of the Institut Pasteur de Lille,
Gravelines, France, and Kansai Medical University, Moriguchi,
Osaka, Japan.
All the experiments were performed after approval by the ethics
committee for animal experimentation from the NordePas de Cal-
ais Region, France.
This work was supported in part with grants from “European
Genomic Institute for Diabetes” (E.G.I.D., ANR-10-LABX-46) and Eu-
ropean Commission; Fondation pour la Recherche Medicale “Deﬁs
en Allergologie”; the Academic Society for Research in Otolaryn-
gology, Kansai Medical University; MEXT-Supported Program for
the Strategic Research Foundation at Private Universities
(S1201038); Grants-in-Aid for Scientiﬁc Research from the Japanese
Ministry of Health, Labour and Welfare (H26-, H27-Research on
measures for intractable disease-general-004).Conﬂict of interest
The authors have no conﬂict of interest to declare.
Akira Kanda a,b,c,d,*, Sebastien Fleury b,c,d, Yoshiki Kobayashi a,
Koichi Tomoda a, Valerie Julia e,f, David Dombrowicz b,c,d
a Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University,
Osaka, Japan
b Inserm U1011, Lille, France
c Institut Pasteur de Lille, Lille, France
d Universite Lille 2, Lille, France
e Inserm U924, Valbonne, France
f Universite de Nice, Valbonne, France
* Corresponding author. Department of Otolaryngology, Head and Neck Surgery,
Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka 573-1010, Japan.
E-mail address: akanda@hirakata.kmu.ac.jp (A. Kanda).References
1. Driss V, Legrand F, Hermann E, Loiseau S, Guerardel Y, Kremer L, et al. TLR2-
dependent eosinophil interactions with mycobacteria: role of alpha-defensins.
Blood 2009;113:3235e44.
2. Woerly G, Roger N, Loiseau S, Dombrowicz D, Capron A, Capron M. Expression
of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cy-
tokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a
complexes. J Exp Med 1999;190:487e95.
3. Shi HZ, Humbles A, Gerard C, Jin Z, Weller PF. Lymph node trafﬁcking and an-
tigen presentation by endobronchial eosinophils. J Clin Invest 2000;105:
945e53.
4. Kobayashi T, Iijima K, Kita H. Marked airway eosinophilia prevents develop-
ment of airway hyper-responsiveness during an allergic response in IL-5 trans-
genic mice. J Immunol 2003;170:5756e63.
5. Kanda A, Driss V, Hornez N, Abdallah M, Roumier T, Abboud G, et al. Eosino-
phil-derived IFN-gamma induces airway hyperresponsiveness and lung inﬂam-
mation in the absence of lymphocytes. J Allergy Clin Immunol 2009;124:
573e82.
6. Iwamoto I, Nakajima H, Endo H, Yoshida S. Interferon gamma regulates antige-
ninduced eosinophil recruitment into the mouse airways by inhibiting the
inﬁltration of CD4þ T cells. J Exp Med 1993;177:573e6.
7. Kumar RK, Herbert C, Webb DC, Li L, Foster PS. Effects of anticytokine therapy
in a mouse model of chronic asthma. Am J Respir Crit Care Med 2004;170:
1043e8.
8. Ishihara C, Ochiai K, Kagami M, Takashahi H, Matsuyama G, Yoshida S, et al. Hu-
man peripheral eosinophils express functional interferon-gamma receptors
(IFN-gamma R). Clin Exp Immunol 1997;110:524e9.
9. Li X, Hawkins GA, Ampleford EJ, Moore WC, Li H, Hastie AT, et al.
Genome-wide association study identiﬁes TH1 pathway genes associated
with lung function in asthmatic patients. J Allergy Clin Immunol 2013;132:
313e20.
10. Steinke JW, Liu L, Huyett P, Negri J, Payne SC, Borish L. Prominent role of IFN-g
in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol
2013;132:856e65.
11. Vale-Pereira S, Todo-Bom A, Geraldes L, Schmidt-Weber C, Akdis CA, Mota-
Pinto A. FoxP3, GATA-3 and T-bet expression in elderly asthma. Clin Exp Allergy
2011;41:490e6.
Received 22 January 2015
Received in revised form 18 March 2015
Accepted 27 March 2015
Available online 1 May 2015
